 |
Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform – BDDS™ – to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 /PRNewswire/ — BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging the Biorchestra Drug Delivery System (BDDS™), which combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics, today announced an exclusive research, option, and licensing agreement with a global biopharmaceutical company focused on developing transformative medicines. The companies will collaborate on an initial target with the option to expand the collaboration to include several additional targets.
Commenting on the transaction, Dr. Branden Ryu, Scientific Founder, Chairman, and Chief Executive Officer, said, "We are excited to begin this collaboration with our U.S. partner. Together we will accelerate a development program to deliver transformational new medicines for patients."
"Our partner’s approach represents a new category of next-generation medicines that our proprietary platform and targeted cell delivery capabilities are ideally suited for," said Dr. Louis St. L. O’Dea, President and Chief Medical Officer. "By leveraging Biorchestra’s suite of technologies that enable IV-formulated, biological-barrier crossing therapeutics, the potential to treat a range of diseases is extremely promising," Dr. O’Dea continued.
"This partnership showcases the inherent value of our transformational science and technology platform within the global pharmaceutical and biotech sector," said Mr. Young Gil Kim, Chief Financial Officer. "Strategic partnerships are an essential element of our global strategy and what will accelerate market access to our breakthrough innovations," Mr. Kim concluded.
Destum Partners acted as transaction advisor to the Company.
About Biorchestra Drug Delivery System (BDDS™)
Formulated for IV administration, the BDDS™ platform targets an amino acid receptor in the blood-brain barrier shared by neurons, astrocytes, and microglia. In addition to significant functional outcomes in a non-human primate study of Alzheimer’s disease, BDDS™ has been leveraged with Antisense Oligonucleotide and siRNA to validate significant knockdown of a target implicated in Amyotrophic Lateral Sclerosis and Parkinson’s disease. Ongoing company discovery and development research will leverage BDDS™ for other underserved diseases, such as Glioblastoma multiforme, Lewy body dementia, Spinocerebellar ataxia type three, Frontotemporal dementia, and Progressive supranuclear palsy.
About BIORCHESTRA
BIORCHESTRA is a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System by leveraging its proprietary BDDS™ platform and its Brain-Targeting RNAi Nanomedicine (BTRiN™) platform. These technologies combine targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics. The company’s lead program, BMD-001, is under development for efficient and effective IV administration targeting specific micro-RNA associated with neuroinflammation, mitochondrial dysfunction, neurodegeneration, and amyloid protein deposition in Alzheimer’s diseasae and Amyotrophic Lateral Sclerosis. The company has extensive research and development and GMP manufacturing capabilities in Daejeon, South Korea, and a U.S. headquarters in Cambridge, Massachusetts, U.S.A. For more information, visit: www.biorchestra.com and follow us on Twitter @biorchestra and LinkedIn.
About BMD-001
Lead drug program targeting specific micro-RNA overexpressed in neurological diseases. An IV formulation of BMD-001 has successfully demonstrated the suppression of specific microRNA across rodent and primate models, normalizing homeostatic processes, reducing amyloid and tau protein deposition, reducing neuroinflammation, and improvements in cognitive function.
Safe Harbor Statement
This press release contains forward-looking statements. In addition, from time to time, our representatives or we may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including our financial performance and projections, revenue and earnings growth, and business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including our ability to change the company’s direction, keep pace with new technology and evolving market needs, and the competitive environment of our business. These and other factors may cause our results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by our representatives or us may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether due to uncertainties and assumptions, the forward-looking events discussed in this press release, and other statements made from time to time by our representatives or us might not occur.
Investor Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
One Rockefeller Plaza, 10th Floor
New York, NY 10020 USA
Office: (646) 893-5835 x2
Email: info@skylineccg.com